Charles A Kunos1,2, Edward Chu3, Jan H Beumer3,4,5, Mario Sznol6, S Percy Ivy7. 1. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA. charles.kunos@nih.gov. 2. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, Rockville, MD, 20892-9760, USA. charles.kunos@nih.gov. 3. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4. Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 5. University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA. 6. Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. 7. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
Abstract
PURPOSE: Advanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition. METHODS: A dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48-96 mg/m2) and i.v. cisplatin (20-75 mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine-cisplatin combination. Secondary endpoints included the rate of triapine-cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323). RESULTS: The MTD was 96 mg/m2 triapine daily days 1-4 and 75 mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%. CONCLUSIONS: The triapine-cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.
PURPOSE: Advanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition. METHODS: A dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48-96 mg/m2) and i.v. cisplatin (20-75 mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine-cisplatin combination. Secondary endpoints included the rate of triapine-cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323). RESULTS: The MTD was 96 mg/m2 triapine daily days 1-4 and 75 mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%. CONCLUSIONS: The triapine-cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.
Entities:
Keywords:
Advanced malignancies; Cisplatin; Dose-limiting toxicity; Maximum tolerated dose; Oral bioavailability; Phase I clinical trial; Triapine
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Charles A Kunos; Tomas Radivoyevitch; Adam Kresak; Dawn Dawson; James Jacobberger; Bin Yang; Fadi W Abdul-Karim Journal: Int J Gynecol Cancer Date: 2012-11 Impact factor: 3.437
Authors: Christopher A Barker; William E Burgan; Donna J Carter; David Cerna; David Gius; Melinda G Hollingshead; Kevin Camphausen; Philip J Tofilon Journal: Clin Cancer Res Date: 2006-05-01 Impact factor: 12.531
Authors: Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella Journal: Radiat Res Date: 2010-09-10 Impact factor: 2.841
Authors: Charles A Kunos; Tomas Radivoyevitch; Steven Waggoner; Robert Debernardo; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Raymond Redline; Peter Faulhaber; Afshin Dowlati Journal: Gynecol Oncol Date: 2013-04-18 Impact factor: 5.482
Authors: Ana Popović-Bijelić; Christian R Kowol; Maria E S Lind; Jinghui Luo; Fahmi Himo; Eva A Enyedy; Vladimir B Arion; Astrid Gräslund Journal: J Inorg Biochem Date: 2011-07-31 Impact factor: 4.155
Authors: Soumya Poddar; Edmund V Capparelli; Ethan W Rosser; Raymond M Gipson; Liu Wei; Thuc Le; Michael E Jung; Caius Radu; Mina Nikanjam Journal: Biochem Pharmacol Date: 2019-12-06 Impact factor: 5.858
Authors: Anand Joshi; Brian F Kiesel; Nupur Chaphekar; Reyna Jones; Jianxia Guo; Charles A Kunos; Sarah Taylor; Edward Chu; Raman Venkataramanan; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2020-09-28 Impact factor: 3.333
Authors: Julia Matsumoto; Brian F Kiesel; Robert A Parise; Jianxia Guo; Sarah Taylor; Marilyn Huang; Julie L Eiseman; S Percy Ivy; Charles Kunos; Edward Chu; Jan H Beumer Journal: J Pharm Biomed Anal Date: 2017-08-31 Impact factor: 3.935
Authors: Kateryna Ohui; Iryna Stepanenko; Iuliana Besleaga; Maria V Babak; Radu Stafi; Denisa Darvasiova; Gerald Giester; Vivien Pósa; Eva A Enyedy; Daniel Vegh; Peter Rapta; Wee Han Ang; Ana Popović-Bijelić; Vladimir B Arion Journal: Biomolecules Date: 2020-09-19